Eme Reorganization (EMEZU) 0.0062 $EMEZU EME

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Eme Reorganization (EMEZU) 0.0062 $EMEZU

EME Reorganization Trust Announces Cash Distribution
PR Newswire - Tue Mar 10, 7:00AM CDT
EME Reorganization Trust (OTCBB: EMEZU) announced that its board of managing trustees has approved a net cash distribution of $0.02674 per beneficial interest. The distribution will be paid on March 31, 2015 to all record holders of beneficial interests as of the close of business on March 20, 2015. Immediately prior to the distribution, there will be 3,853,697,304 issued and outstanding beneficial interests of the Trust.

EME Reorganization Trust reports USD0.1009262 per beneficial interest dividend
M2 - Thu Oct 16, 4:09AM CDT
The board of managing trustees of EME Reorganization Trust (Other OTC:EMEZU), a liquidate assets company, on Wednesday declared a distribution of USD0.1009262 per beneficial interest.

EME Reorganization Trust concludes sale of EIX notes
M2 - Fri Sep 26, 3:01AM CDT
EME Reorganization Trust (Other OTC:EMEZU) revealed on Thursday the completion of the sale of certain zero coupon unsecured notes (the EIX notes) to an unaffiliated third party for an aggregate purchase price of USD400.21m.
EIX: 72.54 (+0.01)

EME Reorganization Trust Closes Sale of EIX Notes
PR Newswire - Thu Sep 25, 7:00AM CDT
EME Reorganization Trust (OTCBB: EMEZU) announced that it has consummated the sale of certain zero coupon unsecured notes (the "EIX Notes" that were previously issued by Edison International (NYSE: EIX) to the EME Reorganization Trust (the "Trust" on September 8, 2014. An unaffiliated third party purchased all the EIX Notes from the Trust at an aggregate purchase price of $400,207,812.94.
EIX: 72.54 (+0.01)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Current Market Sentiment on HealthEquity Shares: A Closer Look

Updated Category News Views 113

Understanding HealthEquity's Short Interest Dynamics HealthEquity Inc (NYSE: HQY) has seen a significant decrease in its short percent of float, which recently dropped by 11.68%. As of the last report, the company had approximately 5.26 million shares sold short, representing 7.03% of its regular shares available for trading. This situation also highlights an average...

Continue Reading
Investors Update: Class Action Against Bumble Inc. Soon

Updated Category News Views 104

Update on Class Action Lawsuit Against Bumble Inc. (BMBL) The Law Offices of Frank R. Cruz are reminding investors about an upcoming significant deadline concerning a class action lawsuit against Bumble Inc. This lawsuit affects investors who acquired BMBL securities during the designated Class Period. Understanding the Class Action Lawsuit The class action was initiated...

Continue Reading
Analysis of Williams-Sonoma's Recent Surge and Current Changes

Updated Category News Views 293

Understanding Williams-Sonoma's Recent Stock Movements This week has seen an impressive rise of nearly 30% in shares of Williams-Sonoma, Inc. (NYSE: WSM), but recent trading indicates a slight pullback. Investors are reacting to two key factors: the natural tendency to take profits and the decision of some buyers to exit losing positions as market conditions evolve. The...

Continue Reading
Understanding the Arconic Corporation Class Action Update

Updated Category News Views 139

Overview of the Class Action Lawsuit Against Arconic Corporation Levi & Korsinsky, LLP has recently announced a class action regarding Arconic Corporation (ARNC). This situation affects investors who may have been impacted by alleged securities fraud. The firm aims to represent those who traded Arconic shares during a specified period and seeks to recover losses resulting...

Continue Reading
Cambrex Partners with Lilly to Enhance Biotech Innovations

Updated Category News Views 220

Cambrex's Strategic Collaboration with Eli Lilly Cambrex, a key player in the global contract development and manufacturing organization (CDMO) sector, has announced an exciting new partnership with Eli Lilly and Company to enhance support for biotech collaborators. Through this agreement, Cambrex aims to provide accelerated access to essential clinical development...

Continue Reading